Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor

NCT05038150 is registered in ClinicalTrials.gov with Guangzhou Sinogen Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT05038150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05038150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor
Lead sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 16, 2023
Completion date
August 31, 2028
Enrollment
70 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor